A Broom1, A F Gibson2, J Broom3, E Kirby2, T Yarwood4, J J Post5. 1. School of Social Sciences, University of New South Wales, Sydney, NSW, Australia. Electronic address: a.broom@unsw.edu.au. 2. School of Social Sciences, University of New South Wales, Sydney, NSW, Australia. 3. Department of Medicine, Sunshine Coast Hospital and Health Service, Nambour, QLD, Australia; School of Medicine, The University of Queensland, Brisbane, QLD, Australia. 4. School of Medicine, The University of Queensland, Brisbane, QLD, Australia; Cairns Clinical School, James Cook University, Cairns, QLD, Australia; Department of Medicine, Cairns and Hinterland Hospital and Health Service, Cairns, QLD, Australia. 5. Department of Infectious Diseases, Prince of Wales Hospital, Sydney, NSW, Australia; Prince of Wales Clinical School, The University of New South Wales, Sydney, NSW, Australia.
Abstract
BACKGROUND: Antibiotic optimization in hospitals is an increasingly critical priority in the context of proliferating resistance. Despite the emphasis on doctors, optimizing antibiotic use within hospitals requires an understanding of how different stakeholders, including non-prescribers, influence practice and practice change. AIM: This study was designed to understand Australian hospital managers' perspectives on antimicrobial resistance, managing antibiotic governance, and negotiating clinical vis-à-vis managerial priorities. METHODS: Twenty-three managers in three hospitals participated in qualitative semi-structured interviews in Australia in 2014 and 2015. Data were systematically coded and thematically analysed. FINDINGS: The findings demonstrate, from a managerial perspective: (1) competing demands that can hinder the prioritization of antibiotic governance; (2) ineffectiveness of audit and monitoring methods that limit rationalization for change; (3) limited clinical education and feedback to doctors; and (4) management-directed change processes are constrained by the perceived absence of a 'culture of accountability' for antimicrobial use amongst doctors. CONCLUSION: Hospital managers report considerable structural and interprofessional challenges to actualizing antibiotic optimization and governance. These challenges place optimization as a lower priority vis-à-vis other issues that management are confronted with in hospital settings, and emphasize the importance of antimicrobial stewardship (AMS) programmes that engage management in understanding and addressing the barriers to change.
BACKGROUND: Antibiotic optimization in hospitals is an increasingly critical priority in the context of proliferating resistance. Despite the emphasis on doctors, optimizing antibiotic use within hospitals requires an understanding of how different stakeholders, including non-prescribers, influence practice and practice change. AIM: This study was designed to understand Australian hospital managers' perspectives on antimicrobial resistance, managing antibiotic governance, and negotiating clinical vis-à-vis managerial priorities. METHODS: Twenty-three managers in three hospitals participated in qualitative semi-structured interviews in Australia in 2014 and 2015. Data were systematically coded and thematically analysed. FINDINGS: The findings demonstrate, from a managerial perspective: (1) competing demands that can hinder the prioritization of antibiotic governance; (2) ineffectiveness of audit and monitoring methods that limit rationalization for change; (3) limited clinical education and feedback to doctors; and (4) management-directed change processes are constrained by the perceived absence of a 'culture of accountability' for antimicrobial use amongst doctors. CONCLUSION: Hospital managers report considerable structural and interprofessional challenges to actualizing antibiotic optimization and governance. These challenges place optimization as a lower priority vis-à-vis other issues that management are confronted with in hospital settings, and emphasize the importance of antimicrobial stewardship (AMS) programmes that engage management in understanding and addressing the barriers to change.
Authors: M Santillo; K Sivyer; A Krusche; F Mowbray; N Jones; T E A Peto; A S Walker; M J Llewelyn; L Yardley Journal: J Antimicrob Chemother Date: 2019-11-01 Impact factor: 5.790
Authors: Ben Parsonage; Philip K Hagglund; Lloyd Keogh; Nick Wheelhouse; Richard E Brown; Stephanie J Dancer Journal: Front Microbiol Date: 2017-11-02 Impact factor: 5.640
Authors: J Keizer; N Beerlage-De Jong; N Al Naiemi; J E W C van Gemert-Pijnen Journal: Antimicrob Resist Infect Control Date: 2020-08-05 Impact factor: 4.887